Posted on January 28th, 2015
Mr. Commissiong was appointed President and CEO of Amarantus BioScience in October 2011.
Amarantus BioScience Holdings, Inc. is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine (“Eltoprazine”), a phase 2b ready indication for Parkinson’s Levodopa induced dyskinesia and Adult ADHD. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test (“LymPro Test®”) for Alzheimer’s disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”) and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson’s disease (“NuroPro”) and the discovery of neurotrophic factors (“PhenoGuard”).
First-Mover Advantage in the $3B Alzheimer’s Blood Test Market with a Business Strategy for Significant Near-Term Reve...Read More »
Posted on January 22nd, 2015
As a former biotech and healthcare analyst, one frustrating reality I’ve come to witness is that many of the more intr...Read More »
Posted on January 12th, 2015
Last Friday we announced the news of a global immuno-oncology alliance with Incyte Corporation, subject to regulatory ap...Read More »
Posted on January 8th, 2015
Although the death rate for cardiovascular disease in the U.S. has dropped from its peak in the 1970s by approximately 2...Read More »
Posted on January 7th, 2015
After an extensive search, it is with great pleasure that I have the opportunity today to introduce Dr. David J. Mazzo, ...Read More »
Reveal Insights About Your Company and Industry to Shareholders.
The Chairman's Blog is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. The Chairman's Blog enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. Learn More »